inclusion criteria: \*patients must meet all of the inclusion criteria at the time of screening\* * must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions: * rheumatoid arthritis or adults previously diagnosed with juvenile idiopathic arthritis (analyzed as a single category) * psoriatic arthritis (psa), ankylosing spondylitis (asp), or other spondyloarthritis (spa) * must have completed the 2-dose regimen of either of the two mrna covid-19 vaccines more than 28 days previous to enrollment * must be scheduled for an additional dose of mrna covid-19 vaccination booster (or with plans to schedule booster) within the next 30 days * must have a cell phone capable of receiving text messages, and/or a personal email address * currently receiving one of the medications described in table 1 * must be on stable immunomodulatory therapy for 8 weeks (with no dose changes, or interruptions \> 2 weeks) prior to study enrollment. this would include both the qualifying immunomodulatory drug listed in table 2, as well as any background immunomodulatory therapies (e.g. methotrexate, leflunomide) or glucocorticoids. * must be 18 years of age or older * must live in the united states.

inclusion criteria: \*patients must meet all of the inclusion criteria at the time of screening\* * must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions: * rheumatoid arthritis or adults previously diagnosed with juvenile idiopathic arthritis (analyzed as a single category) * psoriatic arthritis (psa), ankylosing spondylitis (asp), or other spondyloarthritis (spa) * must have completed the 2-dose regimen of either of the two mrna covid-19 vaccines more than 28 days previous to enrollment * must be scheduled for an additional dose of mrna covid-19 vaccination booster (or with plans to schedule booster) within the next 30 days * must have a cell phone capable of receiving text messages, and/or a personal email address * currently receiving one of the medications described in table 1 * must be on stable immunomodulatory therapy for 8 weeks (with no dose changes, or interruptions \> 2 weeks) prior to study enrollment. this would include both the qualifying immunomodulatory drug listed in table 2, as well as any background immunomodulatory therapies (e.g. methotrexate, leflunomide) or glucocorticoids. * must be 18 years of age or older * must live in the united states.

inclusion criteria: *patients must meet all of the inclusion criteria at the time of screening* must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions: rheumatoid arthritis or adults previously diagnosed with juvenile idiopathic arthritis (analyzed as a single category) psoriatic arthritis (psa), ankylosing spondylitis (asp), or other spondyloarthritis (spa) must have completed the 2-dose regimen of either of the two mrna covid-19 vaccines more than 28 days previous to enrollment must be scheduled for an additional dose of mrna covid-19 vaccination booster (or with plans to schedule booster) within the next 30 days must have a cell phone capable of receiving text messages, and/or a personal email address currently receiving one of the medications described in table 1 must be on stable immunomodulatory therapy for 8 weeks (with no dose changes, or interruptions > 2 weeks) prior to study enrollment. this would include both the qualifying immunomodulatory drug listed in table 2, as well as any background immunomodulatory therapies (e.g. methotrexate, leflunomide) or glucocorticoids. must be 18 years of age or older must live in the united states.

inclusion criteria: *patients must meet all of the inclusion criteria at the time of screening* must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions: rheumatoid arthritis or adults previously diagnosed with juvenile idiopathic arthritis (analyzed as a single category) psoriatic arthritis (psa), ankylosing spondylitis (asp), or other spondyloarthritis (spa) must have completed the 2-dose regimen of either of the two mrna covid-19 vaccines more than 28 days previous to enrollment must be scheduled for an additional dose of mrna covid-19 vaccination booster (or with plans to schedule booster) within the next 30 days must have a cell phone capable of receiving text messages, and/or a personal email address currently receiving one of the medications described in table 1 must be on stable immunomodulatory therapy for 8 weeks (with no dose changes, or interruptions > 2 weeks) prior to study enrollment. this would include both the qualifying immunomodulatory drug listed in table 2, as well as any background immunomodulatory therapies (e.g. methotrexate, leflunomide) or glucocorticoids. must be 18 years of age or older must live in the united states.

inclusion criteria: *patients must meet all of the inclusion criteria at the time of screening* - must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions: - rheumatoid arthritis or adults previously diagnosed with juvenile idiopathic arthritis (analyzed as a single category) - psoriatic arthritis (psa), ankylosing spondylitis (asp), or other spondyloarthritis (spa) - must have completed the 2-dose regimen of either of the two mrna covid-19 vaccines more than 28 days previous to enrollment - must be scheduled for an additional dose of mrna covid-19 vaccination booster (or with plans to schedule booster) within the next 30 days - must have a cell phone capable of receiving text messages, and/or a personal email address - currently receiving one of the medications described in table 1 - without any meaningful interruption or change in immunomodulatory therapy since the time of initial vaccine series to the time of study enrollment. dose changes of immunomodulatory therapies are permitted, as are brief interruptions of < 2 weeks - must be 18 years of age or older - must live in the united states.

inclusion criteria: *patients must meet all of the inclusion criteria at the time of screening* - must have a rheumatology provider diagnosis of one or more of the following autoimmune inflammatory conditions: - rheumatoid arthritis or adults previously diagnosed with juvenile idiopathic arthritis (analyzed as a single category) - psoriatic arthritis (psa), ankylosing spondylitis (asp), or other spondyloarthritis (spa) - must have completed the 2-dose regimen of either of the two mrna covid-19 vaccines more than 28 days previous to enrollment - must be scheduled for an additional dose of mrna covid-19 vaccination booster (or with plans to schedule booster) within the next 30 days - must have a cell phone capable of receiving text messages, and/or a personal email address - currently receiving one of the medications described in table 1 - without any meaningful interruption or change in immunomodulatory therapy since the time of initial vaccine series to the time of study enrollment. dose changes of immunomodulatory therapies are permitted, as are brief interruptions of < 2 weeks - must be 18 years of age or older - must live in the united states.